The fecal pancreatic elastase testing market is poised for substantial growth over the next decade. The market is expected to increase from USD 15,306.7 million in 2023 to an impressive USD 31,842.3 million by 2033, capturing a robust Compound Annual Growth Rate (CAGR) of 7.6% from 2023 to 2033.
Further driving the market’s growth are developments in testing technologies, rising point-of-care testing solution acceptance, and rising awareness of the significance of pancreatic disease early detection and treatment.
The global pancreatic cancer market offers numerous opportunities to improve therapy and diagnosis, benefiting patients and healthcare providers alike. As the demand for effective testing and treatment options continues to rise, the market is expected to maintain its upward trajectory, offering significant growth potential.
Request a Sample Copy of This – Report Now
Rising Pancreatic Cancer Rates:
Several factors contribute to the increasing prevalence of pancreatic cancer, including:
- Obesity and Physical Inactivity: These lifestyle factors are linked to an elevated risk of developing pancreatic cancer.
- Dietary Habits: A high-fat diet low in vegetables and high in red and processed meat consumption can increase pancreatic cancer risk.
Improved Treatment Options Spark Optimism:
New developments in therapeutic possibilities provide a glimmer of optimism despite the obstacles. Patients with pancreatic cancer are seeing longer life times thanks to the discovery of novel medication regimens and combinations.
Focus on Early Detection Remains Key:
Even though there are potential new treatment options, improving patient outcomes still heavily depends on early detection. The market for fecal pancreatic elastase testing is essential to this battle since it offers a non-invasive instrument for early detection and better patient care.
Competitive Landscape:
Manufacturers employ a number of crucial strategies to increase their clientele. Including the introduction of new products, developments in technology, collaborations, and distribution contracts amongst industry players.
Recent Development:
- In June 2020, BÜHLMANN unveiled the BÜHLMANN fPELA® turbo, a revolutionary turbidimetric immunoassay. It has received CE certification and is intended to speed up the detection of human pancreatic elastase.
- Pancreatic Elastase-Turbidimetric test, a quantitative turbidimetric test for the detection of human Pancreatic Elastase E1 in human solid stool samples. It was introduced by Vitassay, a developer and distributor of diagnostic tests, in May 2020.
Customization Available – Here
Some Key Companies are as follows:
- Laboratory Corporation of America® Holdings
- DiaSorin
- ScheBo Biotech AG
- Immundiagnostik AG
- Invivo Healthcare
- DRG Instruments GMBH
- Verisana Laboratories
- BÜHLMANN Laboratories AG
- CerTest Biotec S.L.
- R-Biopharm AG
- American Laboratory Products Company, Ltd.
- Vitassay Healthcare, S.L.U.
Key Segments Covered in the Market:
By Product:
- Fecal Pancreatic Elastase ELISA Kits
- Rapid Fecal Pancreatic Elastase Kits
By Indication:
- Chronic Pancreatitis
- Type 1 Diabetes
- Cystic Fibrosis
- Others
By End User:
- Hospitals
- Diagnostics Laboratories
- Specialty Clinics
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa
In-Depth Market Overview – Purchase Now to Access
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
